3-[(十氢-1Β,2Β,4AΒ-三甲基-5-亚甲基-1-萘基)甲基]-2-羟基-5-甲氧基苯醌
| 中文名称 | 3-[(十氢-1Β,2Β,4AΒ-三甲基-5-亚甲基-1-萘基)甲基]-2-羟基-5-甲氧基苯醌 |
|---|---|
| 中文同义词 | 3-[(十氢-1Β,2Β,4AΒ-三甲基-5-亚甲基-1-萘基)甲基]-2-羟基-5-甲氧基苯醌 |
| 英文名称 | ILIMAQUINONE |
| 英文同义词 | 3-[(DECAHYDRO-1B,2B,4AB-TRIMETHYL-5-METHYLENE-1-NAPHTHYL)METHYL]-2-HYDROXY-5-METHOXYBENZOQUINONE;3-[(DECAHYDRO-1BETA,2BETA,4A-BETA-TRIMETHYL-5-METHYLENE-1-NAPHTHYL)-METHYL]-2-HYDROXY-5-METHOXYBENZOQUINONE;3-[(DECAHYDRO-1BETA,2BETA,4A-BETA-TRIMETHYL-5-METHYLENE-1-NAPTHYL)METHYL]-2-HYDROXY-5-METHOXYBENZOQUINONE;3-[(DECAHYDRO-1BETA,2BETA,4ALPHA-BETA-TRIMETHYL-5-METHYLENE-1-NAPHTHYL)METHYL]-2-HYDROXY-5-METHOXYBENZOQUINONE;IQ;ILIMAQUINONE;3-[(decahydro-1β,2β,4aβ-trimethyl-5-methylene-1-naphthyl)methyl]-2-hydroxy-5-methoxybenzoquinone;illimaquinone |
| CAS号 | 71678-03-0 |
| 分子式 | C22H30O4 |
| 分子量 | 358.47 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 71678-03-0.mol |
| 结构式 | ![3-[(十氢-1Β,2Β,4AΒ-三甲基-5-亚甲基-1-萘基)甲基]-2-羟基-5-甲氧基苯醌 结构式](CAS/GIF/71678-03-0.gif) |
3-[(十氢-1Β,2Β,4AΒ-三甲基-5-亚甲基-1-萘基)甲基]-2-羟基-5-甲氧基苯醌 性质
| 熔点 | 108-110℃ (pentane ) |
|---|---|
| 比旋光度 | D23 -23.2° (c = 1.12 in CHCl3) |
| 沸点 | 478.4±45.0 °C(Predicted) |
| 密度 | 1.14±0.1 g/cm3(Predicted) |
| 储存条件 | −20°C |
| 溶解度 | DMSO：可溶；乙醇：可溶；己烷：可溶；甲醇：可溶 |
| 酸度系数(pKa) | 2.92±0.50(Predicted) |
| 形态 | 红色固体 |
| 颜色 | 浅黄至棕色 |
Ilimaquinone 是一种海洋海绵状代谢产物，通过 GADD153 介导的信号通路发挥抗肿瘤活性。Ilimaquinone 可以诱导高尔基体的囊泡化。Ilimaquinone 具有抗病毒，抗菌和抗炎活性。
Ilimaquinone induces a concentration-dependent anti-proliferative effect in several types of cancer cell lines, including prostate cancer PC-3 and LNCaP, non-small cell lung cancer A549 and hepatocellular carcinoma Hep3B cells. Ilimaquinone (0.3-30 μM ; 48 hours) inhibits the proliferation of PC-3 cells, DU145, LNCaP, MG63, A549, Hep3B cells with GI 50 s of 2.6 μM, 5.8, 4.6, 4.9, 4.1, 12.0μM, respectively.
Cell Viability Assay
| Cell Line: | Prostate cancer PC-3 cells |
| Concentration: | 0.3, 1, 3, 10, and 30 μM |
| Incubation Time: | 48 hours |
| Result: | Inhibited the proliferation of PC-3 cells in a concentration-dependent manner. |
Ilimaquinone exhibits terminal elimination half-lives (T 1/2 =1.2±0.3 h) due to high plasma clearance (2.95±0.53 L/h/kg) following oral administration (10 mg/kg) in male Sprague-Dawley rats.
安全信息
| WGK Germany | 3 |
|---|
| 提供商 | 语言 |
|---|---|
|
英文
|